Bicycle Therapeutics Q3 net loss widens as R&D costs rise

Bicycle Therapeutics

30/10/2025 11:12

Overview

Bicycle Therapeutics reports Q3 net loss of $59.1 mln, increased R&D expenses

Company expects dose selection update for pivotal trial in Q1 2026

Strengthened leadership with new Board and Advisory Board appointments

Outlook

Bicycle Therapeutics expects financial runway into 2028

Company to provide Duravelo-2 trial update in 1Q 2026

Initial EphA2 human imaging data expected in 1H 2026

Result Drivers

INCREASED R&D EXPENSES - Higher R&D costs driven by zelenectide pevedotin development and other clinical programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$59.10 mln
Q3 Basic EPS
-$0.85
Q3 Operating Expenses
$77.28 mln
Q3 Operating Incom
-$65.55 mln
Q3 Pretax Profit
-$58.89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $25.50, about 67.9% above its October 29 closing price of $8.18

Press Release: ID:nBw8XBhDCa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)